Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
2.010
-0.110 (-5.19%)
Nov 20, 2024, 4:00 PM EST - Market open
Taysha Gene Therapies Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 9.92 | 15.45 | 2.5 | - | - | - |
| Revenue Growth (YoY) | -30.90% | 517.55% | - | - | - | - |
| Gross Profit | 9.92 | 15.45 | 2.5 | - | - | - |
| Selling, General & Admin | 28.83 | 30.05 | 37.36 | 41.32 | 11.11 | 0.51 |
| Research & Development | 63.57 | 56.78 | 91.17 | 131.94 | 31.89 | 3.95 |
| Operating Expenses | 92.4 | 86.83 | 128.53 | 173.27 | 43 | 4.46 |
| Operating Income | -82.49 | -71.37 | -126.03 | -173.27 | -43 | -4.46 |
| Interest Expense | -0.79 | -5 | -3.8 | -1.43 | -0.03 | - |
| Interest & Investment Income | 7.16 | 3.57 | 0.25 | 0.17 | 0.05 | - |
| Other Non Operating Income (Expenses) | 60.03 | -36.3 | -0.02 | - | -17.03 | - |
| EBT Excluding Unusual Items | -16.09 | -109.1 | -129.59 | -174.52 | -60.01 | -4.46 |
| Asset Writedown | -5.29 | -1.07 | -36.42 | - | - | - |
| Other Unusual Items | -1.4 | -1.4 | - | - | - | - |
| Pretax Income | -22.77 | -111.57 | -166.01 | -174.52 | -60.01 | -4.46 |
| Net Income | -22.77 | -111.57 | -166.01 | -174.52 | -60.01 | -4.46 |
| Net Income to Common | -22.77 | -111.57 | -166.01 | -174.52 | -60.01 | -4.46 |
| Shares Outstanding (Basic) | 236 | 116 | 44 | 38 | 18 | 10 |
| Shares Outstanding (Diluted) | 236 | 116 | 44 | 38 | 18 | 10 |
| Shares Change (YoY) | 203.71% | 164.20% | 16.74% | 113.13% | 83.53% | - |
| EPS (Basic) | -0.10 | -0.96 | -3.78 | -4.64 | -3.40 | -0.46 |
| EPS (Diluted) | -0.10 | -0.96 | -3.78 | -4.64 | -3.40 | -0.46 |
| Free Cash Flow | -79.43 | -76.89 | -109.01 | -132.35 | -30.81 | - |
| Free Cash Flow Per Share | -0.34 | -0.66 | -2.48 | -3.52 | -1.74 | - |
| Gross Margin | 100.00% | 100.00% | 100.00% | - | - | - |
| Operating Margin | -831.93% | -461.94% | -5037.05% | - | - | - |
| Profit Margin | -229.67% | -722.06% | -6635.25% | - | - | - |
| Free Cash Flow Margin | -801.08% | -497.62% | -4356.87% | - | - | - |
| EBITDA | -81.18 | -70 | -124.86 | -172.78 | -42.99 | - |
| D&A For EBITDA | 1.31 | 1.37 | 1.17 | 0.49 | 0.01 | - |
| EBIT | -82.49 | -71.37 | -126.03 | -173.27 | -43 | -4.46 |
Source: S&P Capital IQ. Standard template.
Financial Sources.